These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 33861693)

  • 61. United States Food and Drug Administration Advisory Committee outcomes and agency approval analysis from 2010 to 2015.
    McCormack Z
    J Am Pharm Assoc (2003); 2018; 58(5):530-533. PubMed ID: 30005816
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Public Policy Should Foster Alzheimer's Treatment Availability: Comment on the Draft US Medicare Decision to Limit Payment for Aducanumab (AduhelmTM) to Patients Participating in Clinical Trials.
    Cummings J
    J Prev Alzheimers Dis; 2022; 9(2):241-246. PubMed ID: 35542996
    [No Abstract]   [Full Text] [Related]  

  • 63. Editorial: Targets for Disease-Modifying Therapies in Alzheimer's Disease, Including Amyloid β and Tau Protein.
    Parums DV
    Med Sci Monit; 2021 Jul; 27():e934077. PubMed ID: 34305135
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Aducanumab, a Novel Anti-Amyloid Monoclonal Antibody, for the Treatment of Alzheimer's Disease: A Comprehensive Review.
    Haddad HW; Malone GW; Comardelle NJ; Degueure AE; Kaye AM; Kaye AD
    Health Psychol Res; 2022; 10(1):31925. PubMed ID: 35928986
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Financial Conflicts of Interest at FDA Drug Advisory Committee Meetings.
    Hayes MJ; Prasad V
    Hastings Cent Rep; 2018 Mar; 48(2):10-13. PubMed ID: 29590518
    [TBL] [Abstract][Full Text] [Related]  

  • 66. A carte blanche approval in Alzheimer's.
    Nat Biotechnol; 2021 Jul; 39(7):781. PubMed ID: 34183862
    [No Abstract]   [Full Text] [Related]  

  • 67. Development of Novel Pharmaceutical Agents for Alzheimer's Disease: The Impact of Regulatory Initiatives in Japan and the United States.
    Tsukamoto K
    Clin Ther; 2015 Aug; 37(8):1652-60. PubMed ID: 25801940
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Representativeness of Participants Eligible to Be Enrolled in Clinical Trials of Aducanumab for Alzheimer Disease Compared With Medicare Beneficiaries With Alzheimer Disease and Mild Cognitive Impairment.
    Anderson TS; Ayanian JZ; Souza J; Landon BE
    JAMA; 2021 Oct; 326(16):1627-1629. PubMed ID: 34499725
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Advancing Alzheimer's disease drug review as a national priority.
    Perry DP
    Alzheimers Dement; 2009 Mar; 5(2):180-1. PubMed ID: 19328455
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Landmark Alzheimer's drug approval confounds research community.
    Mullard A
    Nature; 2021 Jun; 594(7863):309-310. PubMed ID: 34103732
    [No Abstract]   [Full Text] [Related]  

  • 71. Alzheimer's drug approval gets a mixed reception.
    Couzin-Frankel J
    Science; 2023 Jan; 379(6628):126-127. PubMed ID: 36634171
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Solanezumab for Alzheimer's disease.
    Samadi H; Sultzer D
    Expert Opin Biol Ther; 2011 Jun; 11(6):787-98. PubMed ID: 21504387
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Doubts persist for claimed Alzheimer's drug.
    Servick K
    Science; 2019 Dec; 366(6471):1298. PubMed ID: 31831649
    [No Abstract]   [Full Text] [Related]  

  • 74. Controversial Alzheimer's drug approval could affect other diseases.
    Mullard A
    Nature; 2021 Jul; 595(7866):162-163. PubMed ID: 34193994
    [No Abstract]   [Full Text] [Related]  

  • 75. Medicare Should Not Cover Aducanumab as a Treatment for Alzheimer's Disease.
    Moghavem N; Henderson VW; Greicius MD
    Ann Neurol; 2021 Sep; 90(3):331-333. PubMed ID: 34278596
    [No Abstract]   [Full Text] [Related]  

  • 76. Failure to demonstrate efficacy of aducanumab: An analysis of the EMERGE and ENGAGE trials as reported by Biogen, December 2019.
    Knopman DS; Jones DT; Greicius MD
    Alzheimers Dement; 2021 Apr; 17(4):696-701. PubMed ID: 33135381
    [TBL] [Abstract][Full Text] [Related]  

  • 77. The evaluation of disease modifying therapies in Alzheimer's disease: a regulatory viewpoint.
    Mani RB
    Stat Med; 2004 Jan; 23(2):305-14. PubMed ID: 14716731
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Paradigm shift in NMDA receptor antagonist drug development: molecular mechanism of uncompetitive inhibition by memantine in the treatment of Alzheimer's disease and other neurologic disorders.
    Lipton SA
    J Alzheimers Dis; 2004 Dec; 6(6 Suppl):S61-74. PubMed ID: 15665416
    [TBL] [Abstract][Full Text] [Related]  

  • 79. Lessons learned from independent central review.
    Ford R; Schwartz L; Dancey J; Dodd LE; Eisenhauer EA; Gwyther S; Rubinstein L; Sargent D; Shankar L; Therasse P; Verweij J
    Eur J Cancer; 2009 Jan; 45(2):268-74. PubMed ID: 19101138
    [TBL] [Abstract][Full Text] [Related]  

  • 80. FDA queries Alzheimer's trial results.
    Marx JL
    Science; 1988 Feb; 239(4843):969. PubMed ID: 3278380
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.